Objectives: To estimate nevirapine (NVP) pharmacokinetics and examine its association with rash and/or hepatotoxicity in women starting antiretroviral treatment in the AIDS Clinical Trials Group A5208/OCTANE study in Africa.
Introduction
Nevirapine (NVP), a nonnucleoside reverse transcriptase inhibitor, is widely prescribed in resource-limited settings as part of initial antiretroviral therapy (ART). As the CD4 cell count threshold for initiating ARTrises globally [1] , it is important to understand the risks of NVP, particularly in women, and among patients with higher CD4 cell counts (>250 cells/ml in women and >400 cells/ml in men) [2] [3] [4] [5] [6] [7] . NVP can be associated with serious and sometimes life-threatening rash and and/or hepatotoxicity during the first 6-18 weeks of therapy.
The exact cause of NVP toxicity remains unclear. A potential relationship between NVP pharmacokinetic exposure and increased risk of toxicity has been proposed but no definitive association has been established [8] [9] [10] [11] [12] [13] [14] . Studies linking NVP pharmacokinetics and toxicity have enrolled predominantly male participants, whereas for women, similar investigations have not been formally conducted. Moreover, women appear to exhibit higher NVP drug exposure compared to men as a result of lower drug clearance [15] . Additionally, the pharmacokinetic disposition of NVP may be influenced by several factors, including body weight, ethnicity, pre-existing liver disease, and pharmacogenetics [14, [16] [17] [18] . Therefore, this study was conducted to clarify the association of NVP pharmacokinetics and the risk of rash and/or liver toxicity in nonpregnant women residing in seven sub-Saharan African countries who started NVP-based antiretroviral treatment in the AIDS Clinical Trials Group (ACTG) A5208/OCTANE clinical trial.
Primary study objectives were to determine NVP pharmacokinetics on the basis of sparse pharmacokinetic sampling from a large cohort of women and examine the association between NVP pharmacokinetics and rash and liver toxicity. A secondary objective was to evaluate the association between NVP toxicity and pretreatment CD4 cell count and weight.
Methods
The demographics of 745 HIV-positive women from 10 African sites enrolled in ACTG 5208/OCTANE, a phase III, open label trial, have been described in detail by Lockman et al. [19] . In brief, women were antiretroviralnaive, apart from use of zidovudine or single-dose NVP for reducing the risk of mother-to-child HIV transmission (MTCT) (in a subset of participants), and had a CD4 cell count at screening of less than 200 cells/ml. Women were randomized 1 : 1 to 400 mg lopinavir/ 100 mg ritonavir twice daily (b.i.d.) or NVP 200 mg daily for 14 days then 200 mg b.i.d., each in combination with tenofovir (tenofovir disoproxil fumarate) 300 mg þ emtricitabine (FTC) 200 mg, administered once daily as the fixed coformulation, Truvada. All 370 women who were randomized to receive NVP (including 121 with prior single-dose NVP exposure for prevention of MTCT and 249 without prior single-dose NVP exposure) were eligible to participate in the NVP pharmacokinetic portion of the study. For the pharmacokinetic study, single random NVP blood samples were collected at 14 (AE 7) days following randomization (that is before NVP b.i.d. dose escalation), and again at 28 (AE 7) days if no NVP doses were missed during the previous 3 days. All women received treatment and were followed until the last woman randomized had completed 48 weeks of follow-up.
NVP plasma concentrations were quantified by liquid chromatography mass spectrometry (LC-tandem-MS) using a method developed and validated within the Drug Research Unit of the Department of Clinical Pharmacy, University of California San Francisco. The method was approved through the Clinical Pharmacology Quality Assurance Program funded by the Division of AIDS and utilizes reverse phase high-pressure liquid chromatography separation coupled with tandem-mass spectrometry detection. NVP and the internal standard were extracted from ethylenediaminetetraacetic acid plasma using percholoric acid precipitation of plasma proteins followed by centrifugation. The supernatant was neutralized with ammonium hydroxide and injected onto a Zorbax-Eclipse XDB-C8 reverse phase column and separated using a gradient elution. Ion pairs 267.4/226.8 for NVP and 628.6/421.2 for internal standard were selected for tandem mass detection in multiple reaction-monitoring mode. The calibration curve concentration range was 50-5000 ng/ml and lower limit of quantification was 50 ng/ml. Inter-assay precision [coefficient of variation (CV), %] ranged from 2.14 to 4.43. Intra-assay coefficient of variation ranged from 2.34 to 13.03%.
Population pharmacokinetic analysis
NVP concentration time data were analyzed using the nonlinear mixed-effects modeling program NONMEM Version 7 (Icon Development Solutions, Ellicott City, Maryland). Variables incorporated in NONMEMincluded measured NVP plasma concentration, dosage, administration time of the last three doses of NVP before sample collection, age, weight, and study site. The first order conditional estimation method with interaction between interindividual variability (IIV) and residual variability was used throughout the model building and evaluation process. Model selection was based on change in the NONMEM objective function value (DOFV), precision of the parameter estimates, and improvements in standard diagnostic plots. Models were compared statistically with a significant set at P < 0.05 (DOFV ¼ À3.84). To evaluate the accuracy and stability of the final pharmacokinetic model, a nonparametric bootstrap resampling method was performed using the NONMEM interface PLT Tools (Version 3.2; PLTsoft, San Francisco, California, USA). A total of 1000 bootstrap datasets were generated from the original data set by repeated sampling with replacement. The median parameter estimates obtained from the bootstrap data set were compared with those obtained by the population pharmacokinetic model.
A one-compartment pharmacokinetic structural model with first-order absorption and elimination was selected. IIV of pharmacokinetic parameters was incorporated using an exponential (log normal) model, and residual (intrasubject) variability was assumed to be a proportional error model. Because only a single NVP blood sample was obtained at weeks 2 and 4 for each participant, a simple additive clearance model was used to capture any induction of clearance after week 2 (clearance week4 ¼ clearance week2 þ clearance additional )
The influence of age and bodyweight on pharmacokinetic parameters was investigated assuming an exponential relationship:
where u j and weight j are the value of the parameter and weight, respectively, for the jth individual, u the typical parameter value in the population standardized to an individual with the median weight at enrollment, and a is the exponent describing the relationship between the parameter and weight.
Definitions of toxicity
All liver or rash events occurring while receiving NVP, or within 7 days after the last dose of NVP and before starting another ART regimen, and deemed to be potentially related to NVP, were designated as toxicity endpoints. Liver toxicity was defined as any grade 2þ transaminase elevation or grade 3þ total bilirubin or alkaline phosphatase elevation according to the DAIDS Adverse Events Grading Tables (Division of AIDS table for grading the severity of adult and pediatric adverse events. December 2004). Laboratory and safety assessments occurred on six separate occasions during the first 24 weeks, every 12 weeks thereafter, and additionally if clinically indicated. NVP was discontinued if participants experienced a grade 3 or 4 rash (or rash of any grade accompanied by other signs/symptoms or laboratory abnormalities suggestive of hypersensitivity reaction), grade 2 or higher transaminase elevations, or increases in liver enzymes by one grade or more (or rash) along with concomitant signs or symptoms of hepatitis.
Statistical analysis
Wilcoxon rank sum test, Wilcoxon signed rank test, and Fisher's exact test were used in the univariate comparisons, and logistic regression was used to fit the multivariable models. In the multivariable models for toxicity endpoints, pretreatment CD4 cell count was categorized as at least 250 cells/ml versus less than 250 cells/ml and pharmacokinetic parameters (log transformed) were analyzed as continuous variables. In the model for efficacy outcomes, a variable indicating pretreatment single-dose NVP exposure was also included because women with such exposure had a higher rate of virologic failure/death than nonexposed women. For grade 3þ rash, due to the small number of events (n ¼ 9), the univariate exact logistic regression including only pharmacokinetic parameter was performed. The following sensitivity analyses were conducted: only including events determined by site investigators as definitely, probably, or possibly NVP related; only including events occurring 6 weeks after treatment initiation; and only including events occurring 18 weeks after treatment initiation. All P-values were two-sided and not adjusted for multiple comparisons.
Results

Baseline demographics
Among the 370 women randomized to a NVP-based regimen, 11 Nevirapine pharmacokinetics NVP concentrations were adequately described by a onecompartment model with first order absorption and elimination. The IIV for volume and oral absorption (k a ) could not be reliably estimated and removal of these random effects did not change the OFVor goodness of fit plots. Therefore, only IIV for clearance was incorporated into the final model. Neither age nor body weight was found to be associated with pharmacokinetic parameters. The final population pharmacokinetic parameters estimates and their confidence intervals are presented in Table 1 . The parameter estimates as found by bootstrap were in agreement with those obtained by the final population pharmacokinetic model ( Table 2) .
Nevirapine toxicity outcomes
We classified NVP toxicity into two major categories, rash of any grade and hepatotoxicity of grade 2þ or more with or without rash (Table 3) . Forty-six (13%) participants discontinued NVP due to liver/rash toxicity (Table 3) . Kaplan-Meier plots show time to first rash and liver toxicity, respectively. (Fig. 1a and b) . The majority of NVP-related rash of any grade (n ¼ 164, 84.5%) and hepatotoxicity (n ¼ 39, 73.6%) developed within the first 18 weeks of therapy ( Fig. 1 ). However, grade 3þ rash occurred earlier by week 5 (seven of nine participants).
Among the 359 women, 194 (54%) developed rash of any grade possibly related to NVP as determined by site investigators; 82 (23%) had grade 2þ and nine (3%) had grade 3þ rashes (one of which also had 3þ liver toxicity). An association between week 4 (but not week 2) NVP pharmacokinetic exposures (i.e. lower week 4 clearance/ F, higher C min , AUC 24 h , and C max ) and a significantly 836 AIDS 2012, Vol 26 No 7 increased odds of grade 3þ rash was observed ( Table 4 ). Median clearance/F was 1.7 l/h for participants exhibiting grade 3þ rash compared to 2 l/h in women without 3þ rash (P ¼ 0.046). The odds of developing grade 3þ rash were estimated to be approximately 50% greater for every 20% decrease in NVP clearance/F (P ¼ 0.046), which corresponds to a 20% increase in NVP AUC 24hr , C max , and C min concentrations ( Table 4 ).
All patients with hepatotoxicity exhibited transaminase elevations except for two women, one with grade 3 alkaline phosphatase and one with grade 3 total bilirubin elevations. Grade 2þ or more hepatotoxicity developed in 53 women (15%); of whom 32 (9%) also had grade 3þ hepatotoxicity (Table 3 ; Fig. 1b ). In 23 women with grade 2þ hepatotoxicity, various grades of rash also occurred. However, only one participant with grade 3þ rash also experienced hepatotoxicity. No significant association was demonstrated between any NVP pharmacokinetic parameters and liver toxicity (data not shown).
Although the number of women with higher pretreatment CD4 cell count was small, these women exhibited an increased risk of hepatotoxicity. Specifically, within the first 18 weeks of treatment and following adjustment for body weight and week 4 clearance/F, women with pretreatment CD4 cell count at least 250 versus less than 250 cells/ml had higher odds of experiencing combined grade 3þ liver/rash toxicity, any liver toxicity, and NVP discontinuation due to liver or rash toxicities ( Table 3 ).
In addition, a greater odds of developing any rash/grade 2þ liver toxicity (odds ratio 3.20, P ¼ 0.038) and a trend toward greater odds of grade 2þ rash (P ¼ 0.046) were observed within 6 weeks but did not persist at 18 weeks. No significant association was observed between pretreatment CD4 cell count at least 250 versus less than 250 cells/ml with rash of any grade. Due to the small number of women with grade 3þ rash, multivariate analysis was not undertaken.
Consistent results were observed across our sensitivity analyses, except that in the models including only NVPrelated events as determined by site investigators, the women with pretreatment CD4 cell count at least 250 cells/ml had higher odds for rash of any grade or liver toxicity/rash of any grade.
Discussion
NVP pharmacokinetics is well characterized in men, but its disposition in women -especially those of sub-Saharan African descent -is less well defined. In this large Nevirapine pharmacokinetics, rash, and hepatotoxicity Dong et al. 837 Table 3 . Overall rates of rash and liver toxicities by pretreatment CD4 cell count. cohort of sub-Saharan African women, we observed a week 4 median NVP clearance/F of 2 l/h, that is approximately 40% lower than clearance/F reported among women from the United States and Europe [16, 18, 20] . This lower-than-expected clearance/F in sub-Saharan African women receiving standard NVP dosing led to higher NVP exposures and an increased risk of grade 3þ rash but not other grades of rash or hepatotoxicity. The odds of developing grade 3þ rash were estimated to be approximately 50% greater for every 20% reduction in week 4 NVP clearance/F and 20% increase in NVP exposures (AUC 24 h , C min , and C max ). NVP rash has been reported to be sex specific, being higher in women than men after adjusting for CD4 cell count [6, 7, 11, 21, 22] . In our study, 54% of participants developed rash compared to previous reports of 6.5-32% [7, 11, 13, [21] [22] [23] . The overall lower NVP clearance in African women along with the greater occurrence of grade 3þ rash associated with higher NVP exposures in our study suggests that lower NVP doses might be appropriate in this population. However, further trials incorporating NVP pharmacogenetic testing in conjunction with pharmacokinetic studies are warranted before dose reductions can be recommended.
Studies comprising more than 80% men report NVP clearance/F to be approximately 3.5 l/h [17, 20, [23] [24] [25] [26] [27] [28] [29] [30] . Overall, women have lower clearance/F than men, although the reasons are not clear; differences in body weight and liver metabolizing capacity have been suggested [17, 18, 25, 26] . Changes in bioavailability are not likely because NVP absorption is high. In ACTG 241, sex significantly affected NVP clearance/F, averaging 3.97 l/h for men compared to 3.02 l/h for women, but women only comprised 10 out of 82 participants [20] . In the 2NN study (n ¼ 1091) with 36% women and 36% of participants from South Africa, steady state median NVP clearance/F among all participants was 2.8 l/h but was 13.8% lower in women [24, 25] . Lower NVP clearances and higher NVP exposures have also been reported in Asians and African-Americans [16, 17, 23, 31] . Additionally, NVP clearance/F may be influenced by geographical region and concomitant hepatitis B and C infection [16, 25] , although no such relationship was observed in our study. However, our cohort included no women with hepatitis C virus and small numbers of hepatitis B virus infected women (n ¼ 25). Median weeks 2 and 4 clearance/F were similar (data not shown) between hepatitis B-infected and noninfected women (P ¼ 0.6). In an intensive NVP pharmacokinetic study of US HIVinfected women, NVP exposure was increased by renal insufficiency and hepatic inflammation and reduced by crack cocaine, high fat diets, and amenorrhea more than 12 months but not age or exogenous administered hormone [16] . Lower clearance rates of ritonavir and saquinavir have also been reported in women compared to men in other studies conducted by the ACTG [32, 33] .
Our results relating NVP exposure and grade 3þ rash in women have not been previously reported. Although a relationship between higher NVP pharmacokinetic exposure and rash and hepatic events has been proposed, no association had been established in either men or women [8, 11, 13, 34] . Moreover, no specific drug concentration predicting NVP toxicity has been identified [10, 13, 30, 35] . The risk of rash was previously found to be more than two-fold higher in participants with NVP concentrations greater than 5.3 mg/l, however, only 10% were women [11] . A higher C max has also been associated with liver enzyme elevations [36] . Other studies have not shown such a consistent relationship [11, 13] . Additionally, pharmacogenetics may play an important role in NVP pharmacokinetics and toxicity and may be responsible for the lower clearance/F observed in this study. Significantly higher NVP pharmacokinetic exposure and a greater risk of skin toxicity were observed in African patients expressing the CYP2B6526TT genotype [14, [37] [38] [39] [40] . In Cambodian HIV-infected patients with the CYP2B6526TT genotype, a lower clearance/F of 1.86 l/h was found, similar to our results. Preliminary findings also suggest the contribution of the adenosine-triphosphate-binding cassette sub-family B member 1 c.3435C>T single-nucleotide polymorphism in NVP hepatotoxicity [41, 42] .
An increased risk of hepatotoxicity was observed in a few women (n ¼ 15) with higher pretreatment CD4 cell count 250 cells/ml or more but screening CD4 cell count less than 200 cells/ml. Some prior studies have reported increased risks of hepatotoxicity and rash for women with CD4 cell count at least 250 cells/ml [43, 44] , whereas others have not [4, [45] [46] [47] [48] [49] . Of note, for participants with 838 AIDS 2012, Vol 26 No 7 per 20% increase in AUC, C max , C min or 20% decrease in CL/F. pretreatment CD4 cell count more than 200 cells/ml but entry CD4 cell count less than 200 cells/ml, we believe these CD4 cell counts are accurate despite the intrapatient variability, as CD4 testing was performed in monitored laboratories that successfully met the requirements of the DAIDS Immunology Quality Assurance program. Furthermore, considerable intrapatient CD4 cell count variability (as much as 200 cells/ml obtained a few weeks apart) has been reported previously [50] [51] [52] [53] .
WHO antiretroviral treatment guidelines recommend NVP as one possible component of initial antiretroviral treatment regimens among persons (including women) with CD4 cell count less than 350 cells/ml [1] . Our results add to previous data suggesting that vigilance and close monitoring for NVP toxicity are required for all African women starting NVP at any CD4 cell count, but toxicity is more likely in those with CD4 cell count at least 250 cells/ml.
Some study limitations should be noted. Oral NVP clearance/F was estimated by NONMEM using two or fewer collected samples after self-reported dosing rather than an intensive pharmacokinetic study. However, the population model appeared to adequately characterize the drug levels. An important limitation is the lack of pharmacogenetic data to correlate with our pharmacokinetic results because patient consent was not initially obtained. Because only sub-Saharan African women were studied, our findings may not be generalizable to other ethnicities. In addition, our findings based on differences between screening and pretreatment CD4 cell counts deserve cautious interpretation due to the small number of women, and the CD4 cell count within-participant fluctuations that might occur between the two measurements.
Conclusion
In our cohort of HIVþ African women, NVP clearance/ F was substantially lower than previous reports, resulting in higher NVP plasma levels and drug exposure. Grade 3þ rash, but not liver toxicity, was significantly associated with a lower week 4 NVP clearance/F. Further pharmacokinetic studies with incorporation of pharmacogenetic testing are recommended, particularly in resource-limited settings, to determine optimal NVP dosages in African women that will maintain efficacy while minimizing toxicity. Consistent with previous findings, baseline CD4 cell count at least 250 cells/ml in a small number of women was significantly associated with NVP liver toxicity and drug discontinuation.
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